Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

Espen Thiis-Evensen¹, Amalie Christine Poole ², Hong-Thien Thi Nguyen², Jon Sponheim³

¹Center for neuroendocrine tumors, Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
²Faculty of Medicine, University of Oslo, Oslo, Norway

Short title: Treatment effect and time to progression in neuroendocrine tumors

Corresponding author:
Espen Thiis-Evensen
Department of Gastroenterology, Oslo University Hospital, Rikshospitalet Sognsvannsveien 20, 0424 Oslo, Norway.
Mobile +47-45039399,
fax: +47-23070670,
ethiisev@ous-hf.no
Abstract

Background: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without a reduction in total tumor load; termed as stable disease (SD). We wanted to investigate whether achieving OR compared to obtaining SD predicted a longer time to progression (TTP) in patients with neuroendocrine tumors (WHO Grade 1 and 2) treated with peptide receptor radionuclide therapy, chemotherapy or molecular targeted therapy. Methods: Patients treated with either peptide receptor radionuclide therapy (PRRT) with $^{177}$Lutetium-DOTA-octreotate, the chemotherapy combination streptozotocin/5-fluorouracil or everolimus were retrospectively assessed to evaluate the effect of the treatments on disease progression. We analyzed the TTP for patients for each treatment modality and compared the TTP between those who achieved OR and those who achieved SD. Results: Altogether 56 patients treated with PRRT, 32 treated with streptozotocin/5-fluorouracil and 52 treated with everolimus were included in the analyses. The median TTP for those treated with PRRT and achieving OR was 31 months, the TTP for those achieving SD was 43 months ($p=0.2$). For patients treated with streptozotocin/5-fluorouracil the results were: OR: 18 months, SD: 23 months ($p=0.9$) and for those treated with everolimus; OR: 9 months, SD: 20 months ($p=0.5$), respectively. We found no differences between patients achieving OR compared to SD regarding age, sex, stage, primary tumor location, Ki-67% or ongoing treatment with somatostatin analogues. Conclusions: We found no treatment benefit with regard to TTP for our patients that experienced OR compared to those who achieved SD, but a trend toward longer TTP among patients with SD.


**Background**

Neuroendocrine tumors (NET) are a heterogeneous group of tumors arising from neuroendocrine cells. Their incidence is increasing worldwide. In Norway the registered increase has been from 5.3 per 100,000 in 1993-2001 to 7.0 in 2006-2010 (1). Most NETs, about 70%, arise from the gastro-entero-pancreatic system (1,2). Surgery is as of today the only treatment modality that can cure the patient. More than 50% of the patients, however, presents with unresectable disseminated disease, often as an incidental finding. There are several treatment modalities that have been shown to reduce the tumor load or stop tumor growth. The most commonly used are somatostatin analogues, molecular targeted therapy (everolimus, sunitinib), peptide receptor radionuclide therapy (PRRT), and chemotherapy (3-8). Traditionally, studies reporting the effect of these treatments have put most emphasis on the tumor load reducing effect (objective response; OR). Less emphasis has been put on the treatments ability to stop tumors growth without necessarily reducing the total tumor volume (disease stabilization, stable disease; SD). In our clinical practice, we have had the impression that NET patients who have an objective response often seem to have a shorter time to progression than those who achieve disease stabilization. We wanted to investigate whether there was a difference in the time to progression (TTP) for patients with non-curable neuroendocrine tumors that experience an OR compared to those where SD.

**Methods**

**Patients**

All patients were treated at our center, a European Neuroendocrine Tumor Society (ENETS) accredited Center of Excellence in the treatment and care for patients with NETs, with a catchment area of 2.8 million people. We identified all patients treated with PRRT, the chemotherapy combination streptozocin/5-fluorouracil (stz/5-FU) or everolimus and they were retrospectively evaluated for treatments effects.

**Stz/5-FU**
This chemotherapy combination was mainly given to patients with pancreatic NETs as first-line treatment. The chemotherapy was administrated as a 5-days induction course followed with one-day cycles every three weeks. Seventy-two patients were evaluated. They received their treatment between April 2007 and May 2017. The best treatment effect based on radiological assessment (see below) was OR in 27 (38%), SD in 16 (22%) and progressive disease (PD) in 29 (40%) patients. Median progression-free survival was 11 months.

PRRT

At our institution PRRT is usually given as second- or third-line treatment. Altogether 79 patients were treated with a median of 4 cycles with $^{177}$Lutetium-DOTA-octreotate (9). They received their PRRT treatment in the period of January 2006 to March 2014. The best treatment effect based on radiological assessment (see below) was OR in 42 (53%), SD in 17 (22%) and progressive disease (PD) in 20 (25%) patients. Median progression free survival was 28 months.

Everolimus

Everolimus is used as a second- to fifth-line of treatment and a total of 98 patients who received treatment between December 2008 and September 2017 were evaluated. The best treatment effect based on radiological assessment (see below) was OR in 15 (15%), SD in 45 (46%) and progressive disease (PD) in 14 (14%) patients. Median progression-free survival was 8.2 months.

Radiological assessment

The radiological response evaluation was usually performed 6 months after the last cycle of PRRT-treatment and thereafter every 6 months. For patients treated with stz/5-FU and everolimus, response evaluation was performed every three months. The evaluation was performed with contrast-enhanced CT-scans with arterial and portal venous phase or with contrast-enhanced MRI. With our routine evaluation of treatment effect, termed the “conventional method”, progressive disease is defined as detection of new lesions or any unequivocal increase in the size of known tumors when comparing examinations comparable in quality and performed with the same modality and same protocols for contrast enhancement. With this method changes in diameter of a lesion of
1-2 mm were not considered as significant due to minute differences in contrast enhancement between examinations and to small operator differences in performing the measurement of the lesions. Treatment response was defined as objective response (any unequivocal shrinkage of tumors, OR) or stable disease (no changes in number or size of tumors, SD). For patients treated with PRRT radiological response evaluation was also performed according to the RECIST 1.1 criteria (9). These RECIST assessments were performed by one single experienced senior oncology-radiologist.

Inclusion criteria

The inclusion criteria were tissue sample verified neuroendocrine tumor with Ki-67% assessment, WHO grade 1 or 2 (Ki 67 20% or below), metastatic or non-resectable disease, lesions measurable on radiological evaluation, and at least one radiological evaluation after initiating therapy (stz/S-FU, everolimus) or after completed all planned cycles of PRRT. If the same patient had several tissue samples taken, the one with the highest Ki-67% was used to define WHO grade. Only patients with OR or SD as best radiological treatment response (based on the "conventional method") were included.

Statistics

Log-rank test was used to compare survival curves, Mann-Whitney U-test was used to compare continuous variables, Chi-Square (or Fisher’s Exact test when appropriate) was used for testing categorical variables. A p-value below 0.05 was considered statistically significant. Inter-quartile range, the range from the 25th to the 75th centile, was used to present the range in Ki-67% estimates. As this study was exploratory no statistical power analyses were performed. The statistical analyses were performed using SPSS 23.0 software (SPSS Inc., Chicago, Ill.).

Results

In the stz/S-FU group 32 patients, in the PRRT treated group 56 patients and in the everolimus group 52 patients fulfilled the inclusion criteria. The distribution of gender, age, primary tumor location,
stage, previous treatments and ongoing treatment with somatostatin analogues are given in Table 1.

Pancreas and the small intestine were the most common primary sites comprising altogether 74% of the study cohort. Pancreas as the primary tumor location dominated in the group treated with stz/5-FU, comprising 67% of the patients. Almost all patients had distant disease. Stz/5-FU was mostly used as first-line treatment, PRRT third-line and everolimus as fourth-line treatments. Only 1 patient in the stz/5-FU group had previously been treated with PRRT or everolimus whereas 43 (83%) in the everolimus group had previously been treated with stz/5-FU or everolimus (Table 1).

Table 1. Patient characteristics

|                  | Stz/5-FU n=32 | PRRT n=56 | Everolimus n=52 |
|------------------|---------------|-----------|-----------------|
| **Age, years**   |               |           |                 |
| Median (range)   | 65 (28-83)    | 63 (29-79)| 66 (41-81)      |
| **Sex**          |               |           |                 |
| Female           | 20 (63)       | 26 (46)   | 31 (60)         |
| **Primary focus (%)** |            |           |                 |
| Pancreas         | 22 (67)       | 18 (32)   | 17 (33)         |
| Small intestine  | 1 (3)         | 26 (46)   | 19 (37)         |
| Lung             | 3 (9)         | 1 (2)     | 9 (17)          |
| Rectum           | 1 (3)         | 3 (5)     |                 |
| Kidney           |               |           | 1 (2)           |
| Duodenum         | 1 (3)         | 1 (2)     |                 |
| Pheochromocytoma |               |           | 1 (2)           |
| Gastric          | 1 (3)         |           |                 |
| Thymus           |               |           | 1 (2)           |
| Unknown          | 3 (9)         | 5 (9)     | 6 (12)          |
| **Stage**        |               |           |                 |
| Regional         | 2 (6)         | 1 (2)     | 4 (8)           |
| Distant          | 30 (94)       | 55 (98)   | 48 (92)         |
| Previous treatment with PRRT | 1 (3) | -          | 25 (48)         |
| Previous treatment with stz/5FU | -     | 12 (21)   | 18 (35)         |
| Previous treatment with everolimus | 1 (3) | 1 (2)     | -               |
| Previous treatment with stz/5FU and PRRT | -     | -         | 20 (38)         |
| **Number of previous treatments** |       |           |                 |
| Median (mean)    | 0 (0.6)       | 1.9 (2.0) | 3 (2.6)         |
Patient demographics, site of primary and previous treatments with PRRT, Stz/SFU and everolimus, (percent). * Includes all types of tumor targeted treatments, including surgery.

In the group treated with stz/SFU the median TTP for those who achieved objective response was 18 months (95% confidence interval (CI) 12-24), and for those who obtained stable disease 23 months (95% CI: 9-36), p=0.8 (Figure 1). The same figures for those who achieved objective response compared to stable disease in the PRRT group were 43 months (95% CI: 41-44) compared to 31 (95% CI:28-34) p=0.2, and for the everolimus group 9 months (95% CI: 2-17) compared to 20 months (95% CI: 13-26) p=0.5, respectively. If the RECIST criteria were applied for response evaluation in the PRRT treated group instead of the “conventional method”, the median TTP for those who achieved OR compared to those with SD was 39 months (95%CI: 25-52) and 37 months (95%CI: 29-45), p=0.6, (Figure 1). When we compared the factors age, sex, Ki-67% and stage between those with OR and those with SD, we found no statistically significant differences or trends (Table 2). For those treated with stz/SFU and PRRT, a larger proportion of women than men obtained OR, but for everolimus it was vice versa. However, these differences were not statistically significant.

Table 2. Treatment effects
|                          | Streptozocin/S-FU | PRRT                | Everolimus  |
|--------------------------|-------------------|---------------------|-------------|
|                          | OR n=22           | SD n=10             | OR n=12     | SD n=40 | p-value |
| **Age**                  |                   |                     |             |         |         |
| years, median mean)      | 63 (63)           | 65 (65)             | 65 (65)     | 67 (66) | 0,9     |
| **Sex**, female (%)      | 10 (83)           | 2 (17)              | 20 (77)     | 6 (23)  | 0,2     |
| **Ongoing SSA treatment (%)** | 3 (14) | 0 | 21 (54) | 10 (59) | 0,7 |
| **Prior treatments**     | 0 (0,6)           | 0 (0,6)             | 2 (1,8)     | 2 (2,2) | 0,1     |
| Median (mean)            |                   |                     |             |         |         |
| **Ki67%**                |                   |                     |             |         |         |
| Total group              | 10 (10-13)        | 10 (3-13)           | 7 (3,5-10)  | 6 (1-10) | 0,4     |
| Pancreas                 | 10 (8-13)         | 10 (10-14)          | 7 (4-12,5)  | 10 (5,5-10) | 1,0 |
| Small intestinal         | -                 | -                   | 6 (2,5-11,5) | 3 (1-8,5) | 0,4     |
| **Stage**                |                   |                     |             |         |         |
| No. patients (%)         |                   |                     |             |         |         |
| Regional                 | 1 (5)             | 1 (10)              | 1 (3)       | 0       | 0,5     |
| Distant                  | 21 (95)           | 9 (90)              | 38 (97)     | 17 (100) |         |
|                          |                   |                     |             |         |         |
Age, sex, ongoing somatostatin analogue-treatment, prior treatments, Ki 67% and stage for from patients divided into treatment modality and best treatment response; objective response or stable. For Ki 67% data is given for the total patient group and further subdivided into the most common primaries; pancreas and small intestine. SSA: somatostatin analogue. IQR: interquartile range

Discussion

In this study with patients with neuroendocrine tumors grade I-II treated with several classes of tumor targeted treatments, we did not find any statistically differences in TTP between those who achieved OR and those who achieved SD. There was, however, a trend towards shorter TTP for those who achieved OR. To our knowledge this is the first study that systematically compare the TTP in response groups (OR or SD) in tumor targeted therapies. We found no differences in patient- or tumor characteristics that separated the two response groups. Age, Ki 67%, site of primary tumor location and stage were comparable within the two response groups. This may indicate that there could be other biological factors than Ki67% and the known behavior of the different primaries that could influence both the response and the duration of the response to tumor targeted treatment modalities.

The strength of this study was that all patients were well characterized, treated in a single center and none of the patients were lost to follow up. The study has, however, several limitations. The numbers of patients in each group were few and the power to detect differences between the response groups low. Some patients were included in more than one group, i.e. 83% in the everolimus group had previously been treated with stz/5-FU or PRRT, and 38% had received both treatments. This might lead to a selection bias reproducing the same pattern with those with SD tending to have longer TTP for the different treatment modalities studied. Still, this did not alter the main
observation that the patient and tumor characteristics recorded could not explain why those who achieved OR did not obtain a longer TTF, but rather a tendency towards a shorter TTP. Differences in tumor grade is theoretically the most plausible explanation for any differences in TTP between the groups. We found no such difference between the groups with regards to the proliferation marker Ki67% although this could be due to the rather limited number of patients. We cannot know for sure whether the recorded Ki-67% estimates are representative for each of the patients. We know that there is significant intratumor heterogeneity (10) and that there are differences in Ki-67% between primaries and metastases (11). We only have one to three Ki-67% estimates from each patient, and with disseminated disease, this estimate could not be representative for their disease. Some of the Ki-67% assessments were performed by less experienced pathologists and not all samples were reexamined by our institution’s pathologists specialized in neuroendocrine neoplasms. We do not believe, however, that occasional suboptimal evaluation of the proliferation index would systematically bias the assessment, but tend to both over- and underestimate the Ki67%, probably at the same extent.

The method used to assess radiological response in this study is both a strength and a limitation. The most widely used radiological response criteria for radiological response evaluation in treatment studies on neuroendocrine tumors are the Response Evaluation Criteria In Solid Tumors (RECIST 1.0 or 1.1) (12) the Southwest Oncology Group standard response criteria (SWOG) (13) and the WHO criteria (14). These criteria were introduced to evaluate the effect of chemotherapy on tumor burden and are based on measuring the diameter of predefined target lesions as well as detection of any new lesions. In the RECIST-criteria, the most widely used assessment method, the diameters of the target lesions are added, and an increase from the start of treatment, or after initial therapy-induced tumor shrinkage, of 20% or more is defined as progressive disease. A reduction of 30% or more is defined as an objective response. Any change between 20% increase and 30% reduction is classified as stable disease. If new lesions emerge, or if preexisting non-target lesions grow, even if there is no change in the target lesions, the patient is defined as to
have progressive disease. RECIST is far from optimal for evaluating treatment response in slow-
growing malignancies such as neuroendocrine tumors (15). We have previously shown that
assessing treatment response with RECIST gives an unrealistic positive impression of the
treatment effect compared to assessing the treatment response with our “conventional method”
(9). The treatment response in the SD-group based on these criteria varies from a 19% increase to
29% decrease in added target lesion diameter. The heterogeneity in this group restricts our
possibility to detect clinically interesting features as demonstrated in our study where the survival
curves for those treated with PRRT overlaps when the RECIST criteria are used and diverges when
evaluated with the “conventional method” (where any unequivocal change was regarded
significant). The “conventional method” is, however, far from optimal. It lacks standardization
and it is based on one or two radiologist’s overall impression of the tumor status. It is therefore
not suitable in treatment trials or for reproducing results made by other investigators. Our results
indicate, however, that radiological response evaluation systems that are more sensitive to
response changes in neuroendocrine tumors are highly needed.

Conclusion

We found no benefit with regards to TTP, but a trend towards shorter TTP for those who
experienced OR for several tumor targeted therapies compared to those who achieved SD.
List of abbreviations

IQR: interquartile range
5-FU: 5-fluorouracil
NET: Neuroendocrine tumors
PRRT: Peptide receptor radionuclide therapy
SD: Stable disease
SSA: somatostatin analogue
Stz: streptozocin
TTP: Time to progression

Declarations

Ethics approval and consent to participate
The institutional review board approved the study. As this study was an observational study with no intervention, informed consent from the patients was not necessary according to the national standard (Norwegian Health Record Act §6-2, and The Health Personnel Act).

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Competing interests
Espen Thiis-Evensen has received an unrestricted research grants from Novartis and has also received speaker honorarium from Novartis, Ipsen, Pfizer and MSD. Jon Sponheim has received a received speaker honorarium from Ipsen.
Amalie Christine Poole, Hong-Thien Thi Nguyen have no conflicts of interest to declare.

Funding
This study received no funding.

Author’ contributions
Espen Thiis-Evensen has made substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data and has drafted the work and approved the final version.

Amalie Christine Poole and Hong-Thien Thi Nguyen have made substantial contributions or the acquisition and analysis and interpretation of data for the work and have been revising it critically for important intellectual content revising it critically for important intellectual content and approved the final version of the work.

Jon Sponheim has made substantial contributions to the interpretation of data for the work and have been revising it critically for important intellectual content and approved the final version of the work.

Acknowledgements
Not applicable
Figure title and legend

Figure 1. Time to progression.

Time to progression in months for patients achieving stable disease (SD) and objective response (OR) treated with A: streptozotocin/5-FU, B and C: PRRT and D: everolimus. Radiological response evaluation done with the “conventional method” in A, B and D, where any unequivocal change in the
References

1. Boyar Cetinkaya R, Aagnes B, Thiiis-Evensen E, Tretli S, Bergstuen DS, Hansen S. Trends in incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology. 2017;104(1):1-10.

2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342.

3. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63.

4. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33.

5. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977.

6. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10;26(20):3403-10.
7. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135.

8. Clewemar Antonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology. 2016;103(3-4):345-53.

9. Løitegård T, Berntzen DT, Thiis-Evensen E. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. Ann Nucl Med. 2019 Mar;33(3):147-152.

10. Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G, et al. Ki-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? Endocrine. 2017 Sep;57(3):494-502.

11. Richards-Taylor S, Tilley C, Jaynes E, Hu H, Armstrong T, Pearce NW, et al. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors. Pancreas. 2017 Nov/Dec;46(10):1354-1358.

12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.
13. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992 Nov;10(4):239-53.

14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14.

15. de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014 Apr 28;21(3):R105-20.